Li Jing, Meng Huaqing, Cao Wan, Qiu Tian
Department of Psychiatry, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016, China.
Department of Psychiatry, the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016, China.
Neurosci Lett. 2015 Oct 8;606:167-72. doi: 10.1016/j.neulet.2015.08.038. Epub 2015 Aug 24.
Major depressive disorder (MDD) is a prevalent mood disorder. Treatment of MDD includes a variety of biopsychosocial approaches. Glutamate receptor, metabotropic 4 (GRM4) has been implicated in the regulation of MDD and it is seen as an attractive target for drug discovery and development. Here we reported using cellular assays and blood samples from MDD patients and showed that miR-335 was downregulated in individuals with depression compared with healthy controls. Additionally, we confirmed that miR-335 can directly target GRM4, which can further regulated the expression of miR-335. Antidepressant drug treatment with citalopram can upregulate miR-335 expression and downregulate GRM4 expression. These results suggest that miR-335 is associated with the pathophysiology of depression and is a potential target for new antidepressant treatments.
重度抑郁症（MDD）是一种常见的情绪障碍。MDD的治疗包括多种生物心理社会方法。代谢型谷氨酸受体4（GRM4）与MDD的调节有关，被视为药物研发的一个有吸引力的靶点。在此，我们报告了使用来自MDD患者的细胞检测和血液样本，结果显示与健康对照相比，抑郁症患者的miR-335表达下调。此外，我们证实miR-335可直接靶向GRM4，而GRM4又可进一步调节miR-335的表达。用西酞普兰进行的抗抑郁药物治疗可上调miR-335表达并下调GRM4表达。这些结果表明，miR-335与抑郁症的病理生理学相关，是新型抗抑郁治疗的潜在靶点。
